Skip to content

glp1.howSign in

Access Treatment Nutrition Fitness Mental & Social Health Supportive Health Advocacy

Evidence & Sources Conversation Guides Search Learning Paths Glossary FAQs Organizations & Support Tools

glp1.how shares peer information from the GLP-1 community. It is not a medical resource — always consult your clinician.

About Disclaimer Privacy Terms Security glp1.community ↗

Advocacy

Advocacy for patient access and equity.

22 articles · updated Jul 19

Guides

FDA's proposal to keep compounded GLP-1s off the 503B bulks list — and how to comment

In May 2026 the FDA proposed to exclude semaglutide, tirzepatide, and liraglutide from the 503B compounding bulks list — a decision that affects how compounded GLP-1s can be made. The public comment period is open (as reported, through July 30, 2026). Here's what the proposal is, why it matters for access, and how to submit a comment.

The Treat and Reduce Obesity Act (H.R. 4231 / S. 1973): what it is and why it matters

TROA is the primary federal bill aimed at fixing Medicare's exclusion of obesity medications — reintroduced repeatedly for over a decade with bipartisan support, but not yet passed. Here's what it would actually change.

Escalation paths beyond your insurer: commissioners, ombudsmen, and external review

When your insurer's internal appeals are exhausted, you're not out of options. Here's who else you can turn to — state regulators, independent reviewers, and patient ombudsmen — and when each applies.

What to say when your employer's benefits team says no

A "no" from HR or benefits isn't always final — it often just means the current plan year's decision has been made. Here's how to respond productively and keep the door open for next year.

How to write an effective insurance appeal letter

A strong appeal letter directly rebuts the specific denial reason with specific documentation — not a general plea for coverage. Here's a structure to work from.

Advocating for coverage when you don't have a qualifying diagnosis code yet

Coverage criteria are often built around a specific BMI threshold or diagnosis code — but real health risk doesn't always map cleanly onto those numbers. Here's how to build a case when you don't yet technically qualify.

The compounding pharmacy debate: patient access vs. safety regulation

When brand-name GLP-1 supply couldn't meet demand, compounded versions filled the gap for many patients who couldn't otherwise afford or access treatment. Here's the tension between access and safety at the center of that debate.

Why GLP-1 access is uneven across income and race

GLP-1 access isn't distributed evenly — cost, insurance type, and healthcare access all compound along income and racial lines. Here's what drives the disparity and what's being done about it.

Weight stigma in healthcare settings: how to advocate for yourself with a dismissive provider

Weight stigma in clinical care is a documented barrier to good treatment, not just an unpleasant interaction. Here's how to recognize it and advocate for yourself when a provider isn't taking your concerns seriously.

Talking to friends and family who are skeptical about GLP-1 use

"Isn't that the easy way out?" Here's how to respond to skepticism from people close to you, grounded in what GLP-1 medications actually are and do, without needing to justify your medical decisions to everyone.

Obesity as a chronic disease vs. a lifestyle choice: why the framing matters

Whether obesity is treated as a chronic disease or a personal failing shapes everything from insurance coverage to how you're treated in a doctor's office. Here's why the framing itself is a site of advocacy.

What a successful insurance appeal campaign looks like

A well-run appeal isn't just a form — it's a small campaign with documentation, timing, and escalation built in. Here's what separates appeals that succeed from ones that stall.

Sharing your story: how patient testimonials influence coverage decisions and legislation

Data moves policy slowly; stories move it faster. Here's why personal testimony carries real weight with lawmakers and insurers, and how to share yours effectively and safely.

How to find and join a GLP-1 patient advocacy or support community

You don't have to navigate GLP-1 treatment or advocacy alone. Here's how to find legitimate patient communities and advocacy groups, and what to watch for when evaluating one.

The role of patient advocacy organizations in obesity treatment policy

Coverage and policy change rarely happen from individual effort alone. Patient advocacy organizations run the sustained campaigns behind legislative and insurance shifts — here's what they actually do, and how to plug into one.

How employer self-funded plans decide GLP-1 coverage — and how to make the case for adding it

Self-funded employers have far more control over GLP-1 coverage than most employees realize — including the power to add it. Here's how those decisions get made internally, and how to make a credible case for change.

The push to get Medicare to cover GLP-1 medications for obesity

Medicare is legally barred from covering weight-loss drugs — but covers the same medications for diabetes or heart disease. As of July 2026, a temporary CMS demonstration called the GLP-1 Bridge offers eligible beneficiaries ~$50/month access while the underlying exclusion stays in place. Here's why the gap exists, what the Bridge does and doesn't change, and how patients and advocates are pushing for a permanent fix.

How GLP-1 coverage mandates differ by state

Some states require insurers to cover obesity treatment, including GLP-1 medications — most don't. Here's how state mandates work, why they don't apply to everyone, and how to find out what your state actually requires.

Conversation guides

discussion guide

Talking to your employer about GLP-1 coverage

Many plans are chosen by your employer, not the insurer. Here's how to raise GLP-1 coverage with HR or benefits — who to ask, what to ask for, and how to make the case.

Glossary terms

Obesity Action Coalition (OAC) — A U.S. nonprofit patient advocacy organization focused on obesity education, awareness, and access to treatment.

Resources

Obesity Action Coalition (official site) — The national patient advocacy nonprofit's official site — education, community support, and advocacy resources for people affected by obesity.
The Obesity Society — A scientific and clinical authority on obesity research, treatment, and policy, bringing together researchers, clinicians, and advocates.